𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Advanced bladder cancer: Status of first-line chemotherapy and the search for active agents in the second-line setting

✍ Scribed by David J. Gallagher; Matthew I. Milowsky; Dean F. Bajorin

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
113 KB
Volume
113
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Second-line chemotherapy with fluorourac
Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy : A multicenter AGEO study
✍ Aziz Zaanan; MΓ©lanie Gauthier; David Malka; Christophe Locher; Jean-Marc Gornet; πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 166 KB πŸ‘ 1 views

## Abstract ## BACKGROUND: Small bowel adenocarcinoma (SBA) is a rare tumor with poor prognosis. First‐line platinum‐based chemotherapy is active in patients with advanced SBA, but data regarding second‐line chemotherapy are lacking. The aim of this study was to evaluate the efficacy and tolerabil

Production of P-glycoprotein from the MD
Production of P-glycoprotein from the MDR1 upstream promoter is insufficient to affect the response to first-line chemotherapy in advanced breast cancer
✍ Selina Raguz; Rebecca A. Randle; Eva R. Sharpe; John A. Foekens; Anieta M. Sieuw πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 French βš– 377 KB

## Abstract Multidrug resistance, the phenomenon by which cells treated with a drug become resistant to the cytotoxic effect of a variety of other structurally and functionally unrelated drugs, is often associated with the expression of P‐glycoprotein, an efflux membrane pump coded by the __MDR1 (A

Recent improvement in the survival of pa
Recent improvement in the survival of patients with advanced nonsmall cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy
✍ Alessandra Bearz; Diego Serraino; Lucia Fratino; Massimiliano Berretta; Umberto πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 38 KB πŸ‘ 3 views

A recent article by Hotta and colleagues 1 reports that survival of patients with nonsmall cell lung cancer (NSCLC) improved slowly over time from 1982 to 2002. Authors pooled together 121 phase 3 trials (42,768 patients overall),